BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.The Journal of Biological Chemistry. 2003. 278. 1450-1456.
It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.no studies found for: BMS-345541
References